


Metabolomics using FTMS

François Fenaille


**CEA/Laboratoire d'Etude du Métabolisme des Médicaments
CEA-Saclay**

francois.fenaille@cea.fr

MetaboHUB (2013-2020): French National Infrastructure of Metabolomics and Fluxomics




Pharmacology &
Clinical diagnostic



Nutrition, Health
& Environment



Plant Biology &
Biotechnology




Microbiology,
Biotechnology &
Toxicology

9 tutelles



«Omic»-based approaches



Genotype: part of the genetic makeup of an organism which determines one of its characteristics

Phenotype: observable characteristics or traits of an organism

What is Metabolomics ?

➤ **The term Metabolomics first used in 1998** (Oliver et al, Trends Biotechnol 1998)

➤ **Metabolomics is the comprehensive measurement of *all the small molecules* or metabolites* in a given cell, tissue or organism (i.e., the metabolome)**


➤ **We will consider that **Metabolomics** is equivalent to **Metabonomics****

Metabonomics: "The quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification"

Nicholson et al, Xenobiotica 1999

* no biopolymers (nucleic acids, polypeptides)

Early Metabolomics: What are the origins of the field?




- The idea that changes in tissues and biological fluids are indicative of disease dates back to ancient Greece,
- The urine wheel (1506) describes the possible colors, smells and tastes of urine, and uses them to diagnose disease

Urine Wheel for diagnosing metabolic diseases
(Ulrich Pinder, 1506, book: *Epiphanie Medicorum*)

What is a metabolite?


- Any small organic molecule detectable in the with a molecular weight generally **less than 1000 Da** (or slightly larger,...)
- Includes human and microbial products
- **High chemical and structural variability:** Includes oligonucleotides, sugars, nucleosides, organic acids, amino acids, lipids, steroids, food-derived components, pollutants, drugs and drug metabolites, small peptides, ...

A part of the metabolome...



Metabolites are chemically diverse (10,000+ cpds), making metabolomics a technical challenge

They also range in concentration from fM to mM: ~12 orders of magnitude !



Why measuring metabolites?

➤ “Simple” answer

- Studying the metabolome provides system-wide understanding of biological mechanism and pathways
- Infer enzyme activities
- Reflective of any observable phenotype
- Diagnostics, functional genomics

➤ More complex answer

- Not victims, but actors: metabolites have crucial functions (signaling, effects on enzyme activities,...)
- A cause somewhere in the network can have effects elsewhere

The Metabolome is sensitive to


- **Genotype**
- **Changes in mRNA**
- **Changes in proteins**
- **Associated microbes**
- **Environment: food, disease, treatment, exposure to drugs or toxins,...**




- ↪ *This sensitivity is both an advantage and disadvantage in Metabolomics*
- ↪ *Difficult to identify direct and specific associations between cause and effect...*

Metabolomics: Natural and environment variability

Ex: urine metabolomics



Thevenot et al, J Proteome Res 2015



Dumas ME et al, Anal Chem 2006

Metabolomics and Health

Biomarker Discovery


Biomarkers

↳ *Biomarkers are measurable internal indicators of molecular and/or cellular alterations, that may appear in an organism after or during exposure to a toxicant and possible disease*

- **Biomarker of exposure:** detection of the toxic compound
- **Biomarker of effect:** interaction between the toxicant and a biological target (e.g., DNA adduct)
- **Biomarker of susceptibility:** inter-individual differences in response to toxicants


↳ *Metabolic profiling*

Why is it important?




- The system can restore itself via self-regulatory mechanisms, thereby maintaining health
- Disease develops when the system loses this ability
- understanding transitional biomarker profiles in terms of mechanism and validation is crucial

Analytical Tools



How to detect metabolites in biological media?

Metabolic fingerprint



NMR

- Simple, non invasive
- Rapid
- Robust: analysis of large series of samples
- But:
- Limited sensitivity

GC-EI-MS


- Sensitive
- Reproducible
- Spectral libraries
- But:
- Chemical derivatization of non volatile compounds
- Issue of thermolabile compounds

LC-MS

- Molecular mass of intact compounds
- Analysis of thermolabile compounds
- sensitive
- But:
- Poor inter-platform reproducibility

Metabolomic objectives


- **Differentiate groups** (e.g., healthy subjects vs diseased patients)



- **Quantification:** differences in metabolite concentrations
- **Identification of metabolites that have changed**
- **Systems biology integration:** interactions with genes, proteins

Non-targeted vs. targeted metabolomics


Untargeted metabolomics (Metabolic profiling)



- Semi-quantitative profiling
- LC-HRMS
- Measurement of unexpected changes in known and unknown metabolites (acquisition without any *a priori*)
- Multi- and uni-variate statistical analyses
- > 1,000 metabolites measured
- Identification of (few) relevant metabolites (biomarkers)



Targeted metabolomics (Quantification)



- Absolute quantification of a limited set of metabolites
- LC-MS/MS
- Metabolites known with corresponding standards available
- Multi- and uni-variate statistical analyses
- Validation of biomarker relevance or hypothesis

Main steps of a metabolomic analysis

1. Sample preparation

2. Obtention of metabolic profiles


3. Data treatment and statistical analysis

Evidencing biologically-relevant signals

4. Metabolite annotation and identification

Main steps of a metabolomic analysis

1. Sample preparation



2. Obtention of metabolic profiles

3. Data treatment and statistical analysis

Evidencing biologically-relevant signals

4. Metabolite annotation and identification

Sample preparation

➤ Metabolite pre-extraction and extraction

➤ Quenching (stopping unwanted biochemical reactions)

Inhibit enzymatic activity

e.g., by sudden temperature shock with ice-cold methanol or liquid nitrogen




➤ Minimum sample preparation

Protein precipitation (*e.g.*, plasma deproteinization by methanol)

Lipid extraction

SPE



Sample preparation

➤ How many samples for statistically relevant results?

Study Subjects Per Group

	Cell Culture	Small Animals	Human Studies
Optimal	>7	>10	>50
Rigorous	6-7	8-10	40-50
Acceptable	4-5	6-7	25-40

Fewer Required

- Strong phenotype or treatment effect (toxicology study)
- Repeated sampling from the same subject
- Multiple time points
- Multiple doses of a drug/inhibitor


More Required

- Subtle phenotype or treatment effect (dietary supplements, exercise-induced changes)
- Mixed populations of subjects (mixed gender, wide-ranging age or BMI)
- Multiple-site collections

Main steps of a metabolomic analysis

1. Sample preparation

2. Obtention of metabolic profiles




3. Data treatment and statistical analysis



Evidencing biologically-relevant signals

4. Metabolite annotation and identification


High resolution mass spectrometry detects more metabolites and improves their identification



Yeast metabolic extract, LTQ-Orbitrap @100,000 resolution




ESIMS-based metabolomics



LC-MS

- Sensitive
- High metabolome coverage
- Time consuming




Direct infusion/introduction mass spectrometry (DIMS)

- High throughput
- Lower metabolome coverage

High throughput metabolomics by direct-infusion mass spectrometry (DIMS)

nanoESI/HRMS (Orbitrap, FT-ICR, Q-TOF)




NanoESI/QTOF (-)
Human urine

USA 1000 urine samples





2min/sample
40 metabolites



Japan / USA


High throughput metabolomics by direct-infusion mass spectrometry (DIMS)

DI/FTICRMS



Annotation of 100 metabolites in human plasma samples


HRMS alone does not distinguish isomers !



38 metabolites detected in **C₁₈** conditions
actually correspond to **83 métabolites** in
PFPP conditions.


Value of a multi-LC approach to discriminate between isomers

Isomers of dihydroxybenzoic acid




[(M-H)]-
C₇H₅O₄⁻
153.018

→ Same MS/MS spectra



→ Different retention times




Several complementary chromatographic methods are required to achieve optimal metabolome coverage

270 metabolites identified in human plasma

Up to 27% of isomers!

3 LC/HRMS systems



Main steps of a metabolomic analysis


1. Sample preparation

2. Obtention of metabolic profiles

3. Data treatment and statistical analysis

Evidencing biologically-relevant signals


4. Metabolite annotation and identification



Some online tools




Home	Create Job	View Results	Stored Datasets	FAQ	Account	Contact	Logout
Job ID:	106091	Job Name:	SHAM vs. TNT	Create Date:	2013-04-06 17:14:17		
Parameter (IDP):	HPLC (Q-TOF (2587))	Log:	View Log	Finish Date:	2013-04-06 17:28:03		
Status:	job complete	Total Aligned Features:	8514				
Datasets Used:	SHAM(182831) (control) TNT(182832)						



Tautenhan R et al, Anal Chem 2012



Workflow4metabolomics






Galaxy 4 / Metabolomics workflow canvas showing the following steps:

- Preprocessing:** Includes steps like 'xcms.group', 'xcms.retcor', 'xcms.filter', and 'xcms.filterts'. It involves inputting datasets and performing normalization and quality control.
- Statistics:** Includes 'batch_correction', 'Univariate', and 'Multivariate' analysis steps.
- Annotation:** Includes 'HMR MS search', 'Compute', and 'kegg Compounds' steps for identifying metabolites.

How to build a sample batch to “avoid” experimental biases?

- Add internal standards to all samples
- **Sample randomization is mandatory**
- ~200 samples/batch
- Include blank samples
- **Include Quality Control (QC) samples:**
must be representative biological samples
(e.g., pool of study samples)
- If needed include interbatches QCs




What does a typical sequence look like?

Injection Order	Sample
1	Blank
2	Blank
3	QC
4	QC
5	QC
6	QC
7	QC
8	Blank
9	8x dil. QC
10	4x dil. QC
11	2x dil. QC
12	QC
13	Blank
14	QC
15	Sample 1
16	Sample 2
17	Sample 3
...	...
24	Sample 10
25	Blank
26	QC
27	Sample 11
...	...
36	Sample 20
37	Blank
38	QC
...	...


QCs for equilibration

Diluted QCs for data treatment
(n=3 each)

10 biological samples




LC-MS metabolic profiles




10,000+ signals, 100-1000s metabolites ?

LC-MS data preprocessing (XCMS)



Obtention of peak lists



Few thousands of variables...
(per chromatographic condition!)

Obtention of peak lists: Quality control and data filtering


Samples →

Peak Nr	Retention	Mass	J5-T	J5-T	J5-T	J5-T	J5-T	J5-T	J5-T
1	13.21	100	1.0E+03	1.5E+03	2.4E+05	1.7E+03	2.0E+03	7.9E+04	?
2	13.98	100	1.8E+03	1.5E+03	2.0E+03	1.7E+03	2.0E+03	1.5E+04	?
3	42.25	106	2.0E+05	4.3E+04	2.9E+05	3.5E+04	1.8E+05	2.0E+03	?
4	16.65	111	2.0E+03	3.7E+04	4.5E+04	1.0E+04	3.9E+05	2.5E+04	?
5	16.92	111	2.0E+03	3.7E+04	4.5E+04	2.1E+05	8.3E+04	2.5E+04	?
6	17.26	111	2.0E+03	3.7E+04	4.5E+04	1.6E+05	2.5E+05	7.2E+05	?
7	17.54	111	2.0E+03	3.7E+04	2.3E+05	1.4E+05	4.3E+04	2.5E+04	?
8	18.01	111	2.0E+03	3.7E+04	2.8E+05	1.0E+04	4.3E+04	2.5E+04	?
9	4.19	126	9.4E+04	1.6E+03	6.4E+04	1.7E+04	2.3E+03	1.2E+04	?
10	4.66	126	1.4E+05	1.6E+03	1.3E+05	1.7E+04	2.3E+03	1.2E+04	?
11	4.93	126	2.1E+03	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.2E+04	?
12	5.07	126	1.8E+05	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.5E+05	?
13	5.40	126	1.3E+05	1.6E+03	1.1E+05	1.7E+04	2.3E+03	2.2E+04	?
14	5.86	126	2.1E+03	1.6E+03	1.1E+05	1.7E+04	2.3E+03	4.9E+04	?

1. Repeatability filter

- CV of Internal Standards < 30%
- CV of QC Samples < 30%


2. Intensity and linearity filters



Peak lists now include only analytically relevant signals and are ready for statistical analysis

Few thousands of variables...
(per chromatographic condition)

➤ Correct feature specific drift within a batch






4. Batch correction

- Correct drift across batches

LOESS Algorithm
(Low Order non linear locally Estimated Smoothing Function)

Facilitate data comparison by lowering the number of dimensions

Peak Nr	Ret(min)	Mass	J5-T 060303.02	J5-T 060303.03	J5-T 060303.04	J5-T 060303.05	J5-T 060303.21	J5-T 060303.22
1	13.24	100	1.8E+03	1.5E+03	2.4E+05	1.7E+03	2.0E+03	7.9E+04
2	13.98	100	1.8E+03	1.5E+03	2.0E+03	1.7E+03	2.0E+03	1.5E+04
3	42.25	106	2.0E+05	4.3E+04	2.9E+05	3.5E+04	1.8E+05	2.0E+03
4	16.65	114	2.0E+03	3.7E+04	4.5E+04	1.0E+04	3.9E+05	2.5E+04
5	16.92	114	2.0E+03	3.7E+04	4.5E+04	2.1E+05	8.3E+04	2.5E+04
6	17.26	114	2.0E+03	3.7E+04	4.5E+04	1.6E+05	2.5E+05	7.2E+05
7	17.54	114	2.0E+03	3.7E+04	2.3E+05	1.4E+05	4.3E+04	2.5E+04
8	18.01	114	2.0E+03	3.7E+04	2.8E+05	1.0E+04	4.3E+04	2.5E+04
9	4.19	126	9.4E+04	1.6E+03	6.4E+04	1.7E+04	2.3E+03	1.2E+04
10	4.66	126	1.4E+05	1.6E+03	1.3E+05	1.7E+04	2.3E+03	1.2E+04
11	4.93	126	2.1E+03	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.2E+04
12	5.07	126	1.8E+05	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.5E+05
13	5.40	126	1.3E+05	1.6E+03	1.1E+05	1.7E+04	2.3E+03	2.2E+04
14	5.86	126	2.1E+03	1.6E+03	1.1E+05	1.7E+04	2.3E+03	4.9E+04
15	6.32	126	1.5E+04	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.2E+04
16	10.56	126	1.9E+05	1.6E+03	2.0E+05	9.1E+03	2.3E+03	1.2E+04
17	11.05	126	2.1E+03	1.6E+03	2.4E+03	9.1E+03	2.3E+03	1.2E+04
18	11.33	126	1.0E+05	1.6E+03	1.5E+05	9.1E+03	2.3E+03	1.2E+04
19	11.80	126	2.1E+03	1.6E+03	2.4E+03	9.1E+03	2.3E+03	1.2E+04
20	16.36	126	2.0E+03	1.6E+03	2.4E+04	9.1E+03	2.3E+03	1.2E+04
21	9.04	138	1.9E+03	3.9E+04	2.1E+04	1.4E+04	2.3E+03	2.7E+04
22	4.39	143	2.9E+05	2.4E+05	2.8E+03	2.9E+05	2.9E+04	2.5E+05
23	5.07	143	2.3E+03	2.1E+03	2.5E+05	2.3E+03	1.9E+05	3.2E+05
24	5.20	143	5.5E+05	2.1E+03	1.1E+05	3.6E+04	2.9E+04	3.4E+05
25	26.39	143	1.3E+04	8.3E+04	5.8E+04	2.3E+03	2.9E+04	1.2E+05
26	6.58	153	4.0E+04	1.1E+06	8.9E+04	9.9E+04	3.4E+04	4.5E+04
27	7.12	153	4.0E+04	2.6E+03	8.9E+04	6.1E+04	1.9E+05	3.7E+04
28	6.72	154	4.2E+05	5.0E+05	2.9E+03	2.0E+04	3.1E+03	3.9E+04
29	6.98	154	5.3E+05	2.0E+03	6.3E+05	2.0E+04	2.8E+05	2.1E+05
30	7.66	154	2.2E+03	6.7E+04	2.9E+03	2.0E+04	2.8E+05	2.1E+04
31	17.54	159	2.3E+03	2.0E+03	2.8E+03	3.0E+05	2.7E+03	3.8E+04
32	17.87	159	2.3E+03	2.0E+03	2.8E+03	2.8E+04	2.7E+03	1.1E+05
33	18.42	159	2.3E+03	2.0E+03	2.8E+03	4.2E+05	2.7E+03	3.8E+04



2 types of multivariate analyses

non supervised (PCA): no information provided regarding sample type

supervised (PLS...): Introduction of a factor explaining sample variance to optimize sample distinction (e.g., healthy/disease, gender,...)

+ univariate analyses


Experimental design	Normal distribution (compare means)	For from normal (compare medians)
Compare two unpaired groups	Unpaired t-test	Mann-Whitney
Compare two paired groups	Paired t-test	Wilcoxon signed-rank
Compare more than two unmatched groups	One-way ANOVA with multiple comparison	Kruskal Wallis
Compare more than two matched groups	Repeated-measures ANOVA	Friedman

Main steps of a metabolomic analysis

1. Sample preparation
2. Obtention of metabolic profiles
3. Data treatment and statistical analysis

Evidencing biologically-relevant signals

4. Metabolite annotation and identification



Annotation vs. Identification

- **Annotation:** One (or more) **property** (typically mass) **match to databases** (not necessarily acquired under identical analytical conditions)

- **Identification:** At least two **orthogonal properties** (RT, MS/MS) **compares to authentic chemical standard analyzed under identical conditions**

Annotation procedure

Samples

Variables (Rt-mass)

Peak Nr	Ret(min)	Mass	J5.T 060303.02	J5.T 060303.03	J5.T 060303.04	J5.T 060303.05	J5.T 060303.21	J5.T 060303.22	?
1	13.24	100	1.8E+03	1.5E+03	2.4E+05	1.7E+03	2.0E+03	7.9E+04	?
2	13.98	100	1.8E+03	1.5E+03	2.0E+03	1.7E+03	2.0E+03	1.5E+04	?
3	42.25	106	2.0E+05	4.3E+04	2.9E+05	3.5E+04	1.8E+05	2.0E+03	?
4	16.65	114	2.0E+03	3.7E+04	4.5E+04	1.0E+04	3.9E+05	2.5E+04	?
5	16.92	114	2.0E+03	3.7E+04	4.5E+04	2.1E+05	8.3E+04	2.5E+04	?
6	17.26	114	2.0E+03	3.7E+04	4.5E+04	1.6E+05	2.5E+05	7.2E+05	?
7	17.54	114	2.0E+03	3.7E+04	2.3E+05	1.4E+05	4.9E+04	2.9E+04	?
8	19.01	114	2.0E+03	3.7E+04	2.8E+05	1.0E+04	4.3E+04	2.5E+04	?
9	4.19	126	9.4E+04	1.6E+03	6.4E+04	1.7E+04	2.3E+03	1.2E+04	?
10	4.66	126	1.4E+05	1.6E+03	1.3E+05	1.7E+04	2.3E+03	1.2E+04	?
11	4.93	126	2.1E+03	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.2E+04	?
12	5.07	126	1.8E+05	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.5E+05	?
13	5.40	126	1.3E+05	1.6E+03	1.1E+05	1.7E+04	2.3E+03	2.2E+04	?
14	5.86	126	2.1E+03	1.6E+03	1.1E+05	1.7E+04	2.3E+03	4.9E+04	?
15	6.32	126	1.9E+04	1.6E+03	2.4E+03	1.7E+04	2.3E+03	1.2E+04	?
16	10.56	126	1.9E+05	1.6E+03	2.0E+05	9.1E+03	2.3E+03	1.2E+04	?
17	11.05	126	2.1E+03	1.6E+03	2.4E+03	9.1E+03	2.3E+03	1.2E+04	?
18	11.33	126	1.0E+05	1.6E+03	1.5E+05	9.1E+03	2.3E+03	1.2E+04	?
19	11.80	126	2.1E+03	1.6E+03	2.4E+03	9.1E+03	2.3E+03	1.2E+04	?
20	16.36	126	2.0E+03	1.6E+03	2.4E+04	9.1E+03	2.3E+03	1.2E+04	?
21	9.04	130	1.9E+03	3.9E+04	2.1E+04	1.4E+04	2.3E+03	2.7E+04	?
22	4.39	143	2.9E+05	2.4E+05	2.8E+05	2.9E+05	2.9E+04	2.5E+05	?
23	5.07	143	2.9E+03	2.1E+03	2.9E+05	2.9E+05	1.9E+05	3.9E+05	?
24	5.20	143	5.5E+05	2.1E+03	1.1E+05	3.6E+04	2.9E+04	3.4E+05	?
25	26.39	143	1.3E+04	8.3E+04	5.8E+04	2.3E+03	2.9E+04	1.2E+05	?
26	6.58	153	4.0E+04	1.1E+06	8.9E+04	9.9E+04	3.4E+04	4.9E+04	?
27	7.12	153	4.0E+04	2.6E+03	8.9E+04	1.1E+04	1.9E+05	3.7E+04	?
28	6.72	154	4.2E+05	5.0E+05	2.9E+03	2.0E+04	3.1E+03	3.9E+04	?
29	6.98	154	5.3E+05	2.0E+03	6.3E+05	2.0E+04	2.8E+05	2.1E+05	?
30	7.66	154	2.2E+03	6.7E+04	2.9E+03	2.0E+04	2.8E+05	2.1E+04	?
31	17.54	159	2.3E+03	2.8E+03	2.8E+03	2.8E+05	2.7E+03	3.8E+04	?
32	17.87	159	2.3E+03	2.8E+03	2.8E+03	2.8E+04	2.7E+03	1.1E+05	?
33	18.42	159	2.3E+03	2.0E+03	2.8E+03	4.2E+05	2.7E+03	3.8E+04	?

1. Annotation using publically available databases

Accurate mass (<1ppm)
Isotopic pattern (¹³C, ³⁴S, ¹⁸O,...)
Molecular Formula

Public databases
(HMDB, Metlin, KEGG)






Accurate mass (<1ppm)
Isotopic pattern (¹³C, ³⁴S, ¹⁸O,...)
Molecular Formula
+/- Retention Time

In-house database

2. Annotation using in-house databases

Relevance of spectral databases

One molecule = several ions





➤ **METLIN Database**
(>10,000 metabolites)

➤ Up to 15 in-source fragments

➤ $[M+H]^+$ and $[M-H]^-$ as most abundant species in only 50% of the cases

Relevance of spectral databases


One molecule = several ions



Automated detection of ions, list of annotated features


M/Z	RT	Formula	Compound	Attribution	Annotations (HMDB, KEGG, METLIN)
188.0709	5.28	C ₁₁ H ₁₀ NO ₂	Tryptophan	[(M+H)-(NH ₃)] ⁺	Deethylatrazine 3-amino-2-naphthoic acid Indoleacrylic acid
189.0757	5.28	C ₁₀ [¹³ C]H ₁₀ NO ₂	Tryptophan	[(M+H)-(NH ₃)] ⁺ (13C)	Ethyl Oxalacetate
190.0787	5.28	C ₉ [¹³ C] ₂ H ₁₀ NO ₂	Tryptophan	[(M+H)-(NH ₃)] ⁺ (13C ₂)	
205.0975	5.28	C ₁₁ H ₁₃ N ₂ O ₂	Tryptophan	[(M+H)] ⁺	Tryptophan ethoin Vasicinol Idazoxan Nirvanol
206.1010	5.28	C ₁₀ [¹³ C]H ₁₃ N ₂ O ₂	Tryptophan	[(M+H)] ⁺ (13C)	N-Acetyl-D-fucosamine N-Acetyl-D-quinovosamine
207.1051	5.28	C ₉ [¹³ C] ₂ H ₁₃ N ₂ O ₂	Tryptophan	[(M+H)] ⁺ (13C ₂)	
409.1902	5.28	C ₂₂ H ₂₅ N ₄ O ₄	Tryptophan	[(2M+H)] ⁺	Gly Trp Phe (and isomers) Lys Met Met (and isomers)
410.1938	5.28	C ₂₁ [¹³ C]H ₂₅ N ₄ O ₄	Tryptophan	[(2M+H)] ⁺ (13C)	Tyr Leu Asp (and isomers) Ile Tyr Asp (and isomers) Val Tyr Glu (and isomers)

Usefulness of Relative Isotopic Abundances for metabolite annotation





Weber et al, Anal Chem 2011

¹³C but also ¹⁸O, ³²S,...



... But beware of space charge effects (when too many ions are trapped)



Number of potential chemical formulas






Orbitrap Fusion
@240,000
AGC 2^e5

1.0007 Da measured vs 1.0033 Da expected !!

Metabolite Identification



Comparison of MS/MS spectra



Two types of spectra bring different structural information

Metabolite Identification

4 Levels of confidence


↳ *Metabolomics Standard Initiative criteria*
(Sumner et al, *Metabolomics* 2007)

Level	Confidence of Identity	Level of Evidence
1	Identified compounds	Comparison of two or more independent and orthogonal data with an authentic chemical standard analyzed under identical experimental conditions
2	Putatively annotated compounds	based upon physicochemical properties and/or spectral similarity with public/commercial spectral libraries, without chemical reference standards
3	Putatively characterized compounds	Based upon characteristic physicochemical properties of a chemical class of compounds, or by spectral similarity to known compounds of a chemical class
4	Unknown compounds	Although unidentified or unclassified these metabolites can still be differentiated and quantified based upon spectral data

Formal identification


Example of pantothenic acid in rat urine

RP-LCMS, LTQ-Orbitrap



LEVEL 1
By comparison to pure STD:
Accurate mass, RT, MS2
(2 stereoisomers on HMDB)

MS/MS spectra (@7,500 reso.)



Putative annotation

Human urine, RP-HRMS (LTQ-Orbitrap)

[M-H]⁻ @ m/z 595.3463


XCMS output		CAMERA output				Inter-sample correlation	Public database annotation
Variable number	m/z	Retention time (min)	isotopes	adduct	pcgroup		
1806	303.1443	9.33	**	**	531	NA	**
4883	593.3312	9.34	[881][M] ⁺	**	512	NA	L-Urobilin
4888	594.3368	9.34	[881][M+1] ⁺	**	512	NA	**
4879	595.3463	9.40	[850][M] ⁺	[M-H] ⁻	394	1.00	C-Curarine / L-Urobilinogen
4882	596.3514	9.40	[850][M+1] ⁺				
4878	631.3258	9.40	**				
3787	481.2789	9.48	**				
2753	381.1910	9.53	**				
3834	485.1792	9.61	**				
1255	253.1440	9.67	**				

Urobilinogen or Stercobilinogen
???

LEVEL 2
No pure STD available
2 hits in public databases (accurate mass)
No MS2 spectra in databases
But structural evidence

Urobilinogen

MS/MS





Putative characterization

↪ *S. aureus* metabolic extract, HILIC-HRMS (Q-Orbitrap)

[M-H]⁻ @ m/z 590.0794

MS/MS spectra



UDP-N-acetyl-fucosamine

$C_{17}H_{26}N_3P_2O_{17}$
(1.6 ppm)

$C_{17}H_{26}N_3P_2O_{17}$
(1.3 ppm)

UDP-N-acetylglucosamine
(authentic standard)

UDP
(authentic standard)



Communication

The Time Is Right to Focus on Model Organism Metabolomes

Arthur S. Edison ¹, Robert D. Hall ², Christophe Junot ³, Peter D. Karp ⁴, Irwin J. Kurland ⁵, Robert Mistrik ⁶, Laura K. Reed ⁷, Kazuki Saito ⁸, Reza M. Salek ⁹, Christoph Steinbeck ⁹, Lloyd W. Sumner ¹⁰ and Mark R. Viant ^{11,*}

Table 1. Prioritized list of model organisms that the new MOM task group recommend for deep investigations of their metabolomes.

Kingdom	Latin Name	Common Name
Bacteria	<i>Escherichia coli</i>	-
Fungi	<i>Saccharomyces cerevisiae</i>	yeast
Animal (invertebrate)	<i>Caenorhabditis elegans</i>	nematode
	<i>Daphnia magna</i>	water flea
	<i>Drosophila melanogaster</i> *	fruit fly
Animal (vertebrate)	<i>Danio rerio</i>	zebrafish
	<i>Mus musculus</i>	mouse
Plant	<i>Arabidopsis thaliana</i> **	thale cress
	<i>Medicago truncatula</i>	barrel medic, model legume
	<i>Oryza sativa</i>	rice
	<i>Solanum lycopersicum</i>	tomato


* International Drosophila Metabolomics Curation Consortium [30]; ** Metabolomics subcommittee (chaired by Kazuki Saito) within the Multinational Arabidopsis Steering Committee [31].

Summary and prospects

- **FTMS of great value to the field:** mass accuracy, high resolution (separation of isobaric species), structural elucidation
- **Metabolomics tools** (data acquisition and treatment) **are constantly improving**
- **Still need to standardize** (e.g., MS and MS/MS data acquisition) **and share informatics tools and databases**
- **Imaging mass spectrometry**
- **Ion mobility**
- **Integration of multi-omics data**
- **Toward large-scale quantitative high throughput metabolomics?**
- **How can we expedite metabolite identification?**


Toward large-scale quantitative Metabolomics

Absolute quantification of metabolites




- ¹³C- and/or ¹⁵N based Metabolic labeling
- Chemical labeling
- Derivatization: dansyl chloride...
- High throughput synthesis of deuterated internal standards

Guo K et al, Anal Chem 2009




Taglang C et al, Angew Chem Int Ed 2015

Toward new data acquisition workflows



MetaboLights: Metabolomics data sharing



EMBL-EBI Services Research Training About us

MetaboLights Search

Examples: alanine, Homo sapiens, urine, MTBLS1

Home Browse Studies Browse Compounds Browse Species Analysis Download Help Give us feedback About Submit Study Login

MetaboLights > Search

Search results

Filter your results

Type study compound

Technology mass spectrometry NMR spectroscopy

Organism

Organism Part

Validations Status green red amber

Validations Status Details

222 results, showing 1 to 10 Page 1 of 23

Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals.

Study Identifier	MTBLS237	Organism	Homo sapiens
Study Size	45.66MB	Study Factors	Diagnosis, Age, age at diagnosis, Years with disease , Family disposition, Smoker, Steroid response, Steroid dependency, HB-score, Mayo-score, Extraintestinal manifestations, Drug Treatment Asetylsalicylic acid, Drug Treatment Local Asetylsalicylic acid, Drug Treatment Azathioprine, Drug Treatment 6-mercaptopurine, Drug Treatment Salazopurine, Drug Treatment Systemic steroids, Drug Treatment Local steroids, Drug Treatment Infliximab , Disease Characterisation , Extension,
Submitted by	Karen Atkins		


N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression.

Study Identifier	MTBLS227	Organism	Homo sapiens
Study Size	4.74GB	Study Factors	Biol. Replicate, Tech. replicate, Tumour site, Stage, CDX1/Villin, Sample type,
Submitted by	Stephanie Holst		

A few biological examples

Metabolomics for the study of liver diseases

- **Hepatic Encephalopathy (HE) is a neurological complication observed in patients with liver diseases (e.g., ACLF)**
- **The proportion of cirrhotic patients developing overt HE is about 40-60%**



However, the pathophysiological mechanism of HE remains poorly understood:

- Hyperammonemia
- Inflammation
- Altered permeability of blood-brain barrier

AIM OF THE STUDY. To highlight altered metabolic pathways in HE patients by using CSF LC/MS-based metabolomics


- **patient stratification**
- **pharmacological targets**

Metabolomics for the study of liver diseases

27 control subjects and 14 HE patients




HE and control patients have different CSF-metabotypes



↪ **72 metabolites (over 122 monitored) with altered concentrations in HE**

Metabolomics for the study of liver diseases




CSF metabolomics highlights alterations of metabolic pathways linked to energy metabolism that are not observed in plasma samples.

👉 Energy metabolism as a pharmacological target for HE??


Metabolomics for the study of liver diseases

↪ Presence of drugs highlighted by untargeted Metabolomics




Putative annotation	Samples
Levetiracetam	BM2
Metronidazole	BG9
Fluconazole	MGH9, NQ1, ZG8, AZ0
Diazepam	BC8, MHG9, MP01, NQ1, ZG8
N-Desmethyldiazepam	BC8, MHG9, MP01, NQ1, ZG8
Tazobactam	BG9, NQ1, ZG8
Piperacillin	BG9, NQ1, ZG8
Ciprofloxacin	AZ0, BG9, NQ1, ZG8, SP3
Norfloxacin	CJ3, BC8

Integrating proteomics and metabolomics to understand changes in histone modifications




What's next ? Links between Metabolism/Microbiota/Immunity




Cancer therapies

Anticancer treatment modalities and co-medications (such as antibiotics) affect the integrity of the epithelial barrier.




Microbiome

Gut-resident commensals interacting with epithelial, stromal, endocrine, neural, immune intestinal cells to regulate barrier functions and whole-body metabolism.




Immune responses

The gut microbiota has systemic effects throughout the meta-organism via secretion of anti-inflammatory cytokine/chemokines, metabolites, antimicrobial and neuropeptides.



System biology: Six blind biologists examining an elephant



Acknowledgements

CEA/SPI/LEMM

Florence Castelli
Benoit Colsch
Annelaure Damont
Patricia Lamourette
Marie-Françoise Olivier
Emeline Chu-Van
Pierre Barbier Saint Hilaire
Kathleen Rousseau
Hélène Cazier
Thais Hautbergue

Jean-Claude Tabet
Anna Warnet



Sandra Alves
Estelle Paris
Denis Lesage



CEA/SPI

Christophe Junot
Sandrine Leblois
Laurie Ménez
Emmanuel Favry
Florence Vizet



CEA/LIST

Etienne Thévenot
Natacha Lenuzza
Alexis Delabrière



MedDay

Sandrine Aros
Alexandre Seyer
Stéphanie Oursel
Fanny Leroux
Simon Broudin
Jennife Hamoniaux



And thank you for your attention!!!